Anti-TNF therapy in the management of Behçet's disease—review and basis for recommendations

PP Sfikakis, N Markomichelakis, E Alpsoy… - …, 2007 - academic.oup.com
Behcet's disease (BD) is a multisystem, chronic-relapsing, inflammatory disorder classified
among the vasculitides [1, 2]. It has a worldwide distribution being more prevalent in the …

Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation

PG Theodossiadis, NN Markomichelakis, PP Sfikakis - Retina, 2007 - journals.lww.com
The anti-tumor necrosis factor (TNF) monoclonal antibody infliximab and the soluble TNF
receptor etanercept inhibit the pleiotropic actions of TNF and are widely used for the …

Effect of infliximab on sight-threatening panuveitis in Behcet's disease

PP Sfikakis, PG Theodossiadis, CG Katsiari… - The Lancet, 2001 - thelancet.com
Permanent loss of vision resulting from relapsing ocular inflammation occurs frequently in
patients with Behcet's disease, despite intensive, chronic immunosuppressive therapy …

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades–Behçet disease

…, S Papaefthimiou, N Markomichelakis - Annals of Internal …, 2004 - acpjournals.org
Background: In Adamantiades–Behçet disease, recurrent ocular inflammation may lead to
loss of vision despite continuous immunosuppressive therapy (1-3). Preliminary evidence …

Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography

NN Markomichelakis, I Halkiadakis, E Pantelia… - Ophthalmology, 2004 - Elsevier
PURPOSE: To describe the morphologic characteristics of uveitic macular edema by the use
of optical coherence tomography (OCT) and to investigate the correlation between …

Infliximab for chronic cystoid macular edema associated with uveitis

NN Markomichelakis, PG Theodossiadis… - American journal of …, 2004 - Elsevier
PURPOSE: To assess the efficacy of the anti-TNF monoclonal antibody infliximab in uveitis
patients without clinically evident ocular inflammation and impaired visual acuity because of …

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study

N Markomichelakis, E Delicha, S Masselos… - …, 2011 - academic.oup.com
Objective. To compare a single infusion of the anti-TNF antibody infliximab vs CSs for acute
panuveitis attacks in Behçet's disease (BD). Methods. A prospective, observational study of …

Cytomegalovirus as a cause of anterior uveitis with sectoral iris atrophy

NN Markomichelakis, C Canakis, P Zafirakis, T Marakis… - Ophthalmology, 2002 - Elsevier
OBJECTIVE: To report two cases of recurrent anterior uveitis with sectoral iris atrophy and
ocular hypertension during attacks caused by cytomegalovirus (CMV). DESIGN: Two …

Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients

N Markomichelakis, E Delicha, S Masselos… - American journal of …, 2012 - Elsevier
PURPOSE: To assess the safety and to conduct a preliminary assessment of efficacy of
intravitreal infliximab, an anti–tumor necrosis factor antibody, for sight-threatening relapsing …

Regression of neovascular age-related macular degeneration following infliximab therapy

NN Markomichelakis, PG Theodossiadis… - American journal of …, 2005 - Elsevier
PURPOSE: To describe the effects of the antitumor necrosis factor (TNF) monoclonal
antibody Infliximab systemic therapy on choroidal neovacularisation (CNV) secondary to …